High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 23, Issue 12, 2008, Pages 4016-4020

  Tokmak, Faruk ^a,b   Quack, Ivo ^c   Schieren, Gisela ^c   Sellin, Lorenz ^c   Rattensperger, Dirk ^b   Holland Letz, Tim ^d   Weiner, Stefan M ^d,e   Rump, Lars C ^c  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Kuratorium für Heimdialyse und Nierentransplantation   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Germany)

Author keywords

Calcidiol; Cholecalciferol; Chronic kidney disease; Haemodialysis; Vitamin D

Indexed keywords

ALFACALCIDOL; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; PARATHYROID HORMONE; PHOSPHORUS;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VITAMIN D DEFICIENCY;

CALCIFEDIOL; CHOLECALCIFEROL; DRUG TOLERANCE; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PROSPECTIVE STUDIES; RENAL DIALYSIS; VITAMIN D DEFICIENCY;

EID: 56749151146     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn367     Document Type: Article

References (22)

1. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-S201
2. Adams JS, Clemens TL, Parrish JA et al. Vitamin-D synthesis and metabolism after ultraviolet irradiation of normal and vitamin-D-deficient subjects. N Engl J Med 1982; 306: 722-725
3. Andress D. Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease. Drugs 2007; 67: 1999-2012
4. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004; 89: 5387-5391
5. Bjorkman M, Sorva A, Risteli J et al. Vitamin D supplementation has minor effects on parathyroid hormone and bone turnover markers in vitamin D deficient bedridden older patients. Age Ageing 2008; 37: 6-7
6. Del Valle E, Negri AL, Aguirre C et al. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int 2007; 11: 315-321
7. DeVille J, Thorp ML, Tobin L et al. Effect of ergocalciferol supplementation on serum parathyroid hormone and serum 25-hydroxyvitamin D in chronic kidney disease. Nephrology (Carlton) 2006; 11: 555-559
8. Eastwood JB, Daly A, Carter GD et al. Plasma 25-hydroxy-vitamin D in normal subjects and patients with terminal renal failure, on maintenance haemodialysis and after transplantation. Clin Sci (Lond) 1979; 57: 473-476
9. Ghazali A, Fardellone P, Pruna A et al. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Kidney Int 1999; 55: 2169-2177
10. Goodkin DA, Young EW, Kurokawa K et al. Mortality among hemodialysis patients in Europe, Japan, and the United States: casemix effects. Am J Kidney Dis 2004; 44: 16-21
11. Gurlek A, Pittelkow MR, Kumar R. Modulation of growth factor/cytokine synthesis and signaling by 1alpha,25-dihydroxyvitamin D(3): implications in cell growth and differentiation. Endocr Rev 2002; 23: 763-786
12. Hewison M, Burke F, Evans KN et al. Extra-renal 25-hydroxyvitamin D3-1alpha-hydroxylase in human health and disease. J Steroid Biochem Mol Biol 2007; 103: 316-321
13. Jones G. Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1alphahydroxylase in the classical and nonclassical actions of 1alpha,25-dihydroxyvitamin D(3). Semin Dial 2007; 20: 316-324
14. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet 1998; 351: 805-806
15. Quack I, Zwernemann C, Weiner SM et al. Dihydrotachysterol therapy for hypoparathyroidism: consequences of inadequate monitoring. Five cases and a review. Exp Clin Endocrinol Diabetes 2005; 113: 376-380
16. Saab G, Young DO, Gincherman Y et al. Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 2007; 105: c132-c138
17. Taskapan H, Wei M, Oreopoulos DG. 25(OH) vitamin D3 in patients with chronic kidney disease and those on dialysis: rediscovering its importance. Int Urol Nephrol 2006; 38: 323-329
18. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456
19. Tentori F, Hunt WC, Stidley CA et al.Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-1865
20. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999; 69: 842-856
21. Wintergerst ES, Maggini S, Hornig DH. Contribution of selected vitamins and trace elements to immune function. Ann Nutr Metab 2007; 51: 301-323
22. Zisman AL, Hristova M, Ho LT et al. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 2007; 27: 36-43